Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function.

Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al.; Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: Cardiovascular disease statistics 2021. Eur Heart J 2022;43:716–799. https://doi.org/10.1093/eurheartj/ehab892

Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, et al.; Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007;9:684–694. https://doi.org/10.1016/j.ejheart.2007.04.003

Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569–582. https://doi.org/10.1016/S0735‐1097(99)00630‐0

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333

Kim GH, Uriel N, Burkhoff D. Reverse remodelling and myocardial recovery in heart failure. Nat Rev Cardiol 2018;15:83–96. https://doi.org/10.1038/nrcardio.2017.139

Hnat T, Veselka J, Honek J. Left ventricular reverse remodelling and its predictors in non‐ischaemic cardiomyopathy. ESC Heart Fail 2022;9:2070–2083. https://doi.org/10.1002/ehf2.13939

Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: Myth, magic, or molecular target? J Am Coll Cardiol 2012;60:2465–2472. https://doi.org/10.1016/j.jacc.2012.06.062

Rodrigues PG, Leite‐Moreira AF, Falcao‐Pires I. Myocardial reverse remodeling: How far can we rewind? Am J Physiol Heart Circ Physiol 2016;310:H1402–H1422. https://doi.org/10.1152/ajpheart.00696.2015

Xu H, Duan Y, Yuan X, Wu H, Song Y, Xu J, et al. Residual left ventricular hypertrophy with adverse clinical outcomes in patients with severe aortic stenosis and asymmetric septal hypertrophy after aortic valve replacement. Eur J Cardiothorac Surg 2019;56:343–350. https://doi.org/10.1093/ejcts/ezy486

Rizzello V, Poldermans D, Boersma E, Biagini E, Schinkel AF, Krenning B, et al. Opposite patterns of left ventricular remodeling after coronary revascularization in patients with ischemic cardiomyopathy: Role of myocardial viability. Circulation 2004;110:2383–2388. https://doi.org/10.1161/01.CIR.0000145115.29952.14

Hassell ME, Vlastra W, Robbers L, Hirsch A, Nijveldt R, Tijssen JG, et al. Long‐term left ventricular remodelling after revascularisation for ST‐segment elevation myocardial infarction as assessed by cardiac magnetic resonance imaging. Open Heart 2017;4:e000569. https://doi.org/10.1136/openhrt‐2016‐000569

Motiwala SR, Gaggin HK. Biomarkers to predict reverse remodeling and myocardial recovery in heart failure. Curr Heart Fail Rep 2016;13:207–218. https://doi.org/10.1007/s11897‐016‐0303‐y

Pontone G, Carita P, Rabbat MG, Guglielmo M, Baggiano A, Muscogiuri G, et al. Role of cardiac magnetic resonance imaging in myocardial infarction. Curr Cardiol Rep 2017;19:101. https://doi.org/10.1007/s11886‐017‐0907‐1

Treibel TA, Badiani S, Lloyd G, Moon JC. Multimodality imaging markers of adverse myocardial remodeling in aortic stenosis. JACC Cardiovasc Imaging 2019;12:1532–1548. https://doi.org/10.1016/j.jcmg.2019.02.034

Gonzalez A, Richards AM, de Boer RA, Thum T, Arfsten H, Hulsmann M, et al. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2022;24:927–943. https://doi.org/10.1002/ejhf.2493

Aimo A, Vergaro G, Gonzalez A, Barison A, Lupon J, Delgado V, et al. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2022;24:944–958. https://doi.org/10.1002/ejhf.2522

Frohlich ED, Susic D. Pressure overload. Heart Fail Clin 2012;8:21–32. https://doi.org/10.1016/j.hfc.2011.08.005

Kojima M, Shiojima I, Yamazaki T, Komuro I, Zou Z, Wang Y, et al. Angiotensin II receptor antagonist TCV‐116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch‐mediated cardiomyocyte hypertrophy in vitro. Circulation 1994;89:2204–2211. https://doi.org/10.1161/01.CIR.89.5.2204

Brodsky S, Gurbanov K, Abassi Z, Hoffman A, Ruffolo RR Jr, Feuerstein GZ, et al. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension 1998;32:746–752. https://doi.org/10.1161/01.hyp.32.4.746

Kaneko K, Susic D, Nunez E, Frohlich ED. Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens 1996;14:645–653. https://doi.org/10.1097/00004872‐199605000‐00015

Kai T, Sugimura K, Shimada S, Kurooka A, Takenaka T, Ishikawa K. Inhibitory effects of a subdepressor dose of L‐158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin‐angiotensin system in double transgenic mice with hypertension. Jpn Circ J 1998;62:599–603. https://doi.org/10.1253/jcj.62.599

Nunez E, Hosoya K, Susic D, Frohlich ED. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997;29:519–524. https://doi.org/10.1161/01.hyp.29.1.519

Tamura T, Said S, Harris J, Lu W, Gerdes AM. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin‐angiotensin system. Circulation 2000;102:253–259. https://doi.org/10.1161/01.cir.102.2.253

Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al.; PROVE‐HF Investigators. Association of change in N‐terminal pro‐B‐type natriuretic peptide following initiation of sacubitril‐valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019;322:1085–1095. https://doi.org/10.1001/jama.2019.12821

Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the angiotensin‐receptor neprilysin inhibitor on cardiac reverse remodeling: Meta‐analysis. J Am Heart Assoc 2019;8:e012272. https://doi.org/10.1161/JAHA.119.012272

Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher‐Krainer E, et al.; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double‐blind randomised controlled trial. Lancet 2012;380:1387–1395. https://doi.org/10.1016/S0140‐6736(12)61227‐6

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077

Ennis IL, Alvarez BV, Camilion de Hurtado MC, Cingolani HE. Enalapril induces regression of cardiac hypertrophy and normalization of pHi regulatory mechanisms. Hypertension 1998;31:961–967. https://doi.org/10.1161/01.HYP.31.4.961

Bohm M, Castellano M, Agabiti‐Rosei E, Flesch M, Paul M, Erdmann E. Dose‐dependent dissociation of ACE‐inhibitor effects on blood pressure, cardiac hypertrophy, and beta‐adrenergic signal transduction. Circulation 1995;92:3006–3013. https://doi.org/10.1161/01.cir.92.10.3006

Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A 1982;79:3310–3314. https://doi.org/10.1073/pnas.79.10.3310

Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN; SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302. https://doi.org/10.1056/NEJM199108013250501

Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669–677. https://doi.org/10.1056/NEJM199209033271001

Ostman‐Smith I. Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure‐overload in the rat. Br J Pharmacol 1995;116:2703–2709. https://doi.org/10.1111/j.1476‐5381.1995.tb17230.x

Kobayashi M, Machida N, Mitsuishi M, Yamane Y. Beta‐blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 2004;17:1112–1119. https://doi.org/10.1016/j.amjhyper.2004.07.007

Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J. Effects of beta‐blockers on heart failure with preserved ejection fraction: A meta‐analysis. PLoS One 2014;9:e90555. https://doi.org/10.1371/journal.pone.0090555

Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al.; Carvedilol Hibernating Reversible Ischaemia Trial: Marker of Success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomised controlled trial. Lancet 2003;362:14–21. https://doi.org/10.1016/S0140‐6736(03)13801‐9

Randomised, placebo‐controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997;349:375–380. https://doi.org/10.1016/S0140‐6736(97)80008‐6

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al.; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002;106:2194–2199. https://doi.org/10.1161/01.CIR.0000035653.72855.BF

Palazzuoli A, Bruni F, Puccetti L, Pastorelli M, Angori P, Pasqui AL, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002;4:765–770. https://doi.org/10.1016/s1388‐9842(02)00114‐9

Wollert KC, Drexler H. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial: Carvedilol as the sun and center of the beta‐blocker world? Circulation 2002;106:2164–2166. https://doi.org/10.1161/01.CIR.0000038702.35084.D6

Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left‐ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385–1390. https://doi.org/10.1016/s0140‐6736(00)04560‐8

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al.; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658. https://doi.org/10.1056/NEJM200105313442201

Groenning BA, Nilsson JC, Sondergaard L, Fritz‐Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta‐blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072–2080. https://doi.org/10.1016/S0735‐1097(00)01006‐8

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet 1999;353:2001–2007. https://doi.org/10.1016/S0140‐6736(99)04440‐2

The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): A randomised trial. Lancet 1999;353:9–13. https://doi.org/10.1016/S0140‐6736(98)11181‐9

Choi SW, Han S, Shim WJ, Choi DJ, Kim YJ, Yoo BS, et al. Impact of heart rate reduction with maximal tolerable dose of bisoprolol on left ventricular reverse remodeling. J Korean Med Sci 2018;33:e171. https://doi.org/10.3346/jkms.2018.33.e171

Yamamoto K. β‐Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. J Cardiol 2015;66:189–194. https://doi.org/10.1016/j.jjcc.2015.02.004

Xu X, Wang DW. The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction. Int J Cardiol Heart Vasc 2020;26:100451. https://doi.org/10.1016/j.ijcha.2019.100451

Bergström A, Andersson B, Edner M, Nylander E, Persson H, Dahlström U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler‐echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6:453–461. https://doi.org/10.1016/j.ejheart.2004.02.003

Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta‐blockers in heart failure: Findings from the OPTIMIZE‐HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009;53:184–192. https://doi.org/10.1016/j.jacc.2008.09.031

Yamamoto K, Origasa H, Suzuki Y, Takahashi T, Shinozaki T, Watanabe T, et al.; J‐DHF Investigators. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction – a report from the Japanese Diastolic Heart Failure Study (J‐DHF). J Cardiol 2014;63:424–431. https://doi.org/10.1016/j.jjcc.2013.10.014

Imamura T, Oshima A, Narang N, Kinugawa K. Implication of mineralocorticoid receptor antagonist esaxerenone in patients with heart failure with preserved ejection fraction. Circ Rep 2021;3:660–665. https://doi.org/10.1253/circrep.CR‐21‐0115

von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: The EMMY trial. Eur Heart J 2022;43:4421–4432. https://doi.org/10.1093/eurheartj/ehac494

Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR‐DM‐HF). Circulation 2021;143:516–525. https://doi.org/10.1161/CIRCULATIONAHA.120.052186

Zhang N, Wang Y, Tse G, Korantzopoulos P, Letsas KP, Zhang Q, et al. Effect of sodium‐glucose cotransporter‐2 inhibitors on cardiac remodelling: A systematic review and meta‐analysis. Eur J Prev Cardiol 2022;28:1961–1973. https://doi.org/10.1093/eurjpc/zwab173

Dhingra NK, Mistry N, Puar P, Verma R, Anker S, Mazer CD, et al. SGLT2 inhibitors and cardiac remodelling: A systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Fail 2021;8:4693–4700. https://doi.org/10.1002/ehf2.13645

Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, et al. Effect of sodium‐glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: A meta‐analysis. Cardiovasc Diabetol 2021;20:25. https://doi.org/10.1186/s12933‐020‐01209‐y

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al.; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632. https://doi.org/10.1093/eurheartj/ehab395

Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM, et al. Calcific aortic stenosis. Nat Rev Dis Primers 2016;2:16006. https://doi.org/10.1038/nrdp.2016.6

Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuva AN, et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol 2018;71:860–871. https://doi.org/10.1016/j.jacc.2017.12.035

Bjornstad JL, Skrbic B, Sjaastad I, Bjornstad S, Christensen G, Tonnessen T. A mouse model of reverse cardiac remodelling following banding‐debanding of the ascending aorta. Acta Physiol (Oxf) 2012;205:92–102. https://doi.org/10.1111/j.1748‐1716.2011.02369.x

Ruppert M, Korkmaz‐Icoz S, Li S, Nemeth BT, Hegedus P, Brlecic P, et al. Myocardial reverse remodeling after pressure unloading is associated with maintained cardiac mechanoenergetics in a rat model of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2016;311:H592–H603. https://doi.org/10.1152/ajpheart.00085.2016

Gao XM, Kiriazis H, Moore XL, Feng XH, Sheppard K, Dart A, et al. Regression of pressure overload‐induced left ventricular hypertrophy in mice. Am J Physiol Heart Circ Physiol 2005;288:H2702–H2707. https://doi.org/10.1152/ajpheart.00836.2004

Jang JY, Seo JS, Sun BJ, Kim DH, Song JM, Kang DH, et al. Impact of valvuloarterial impedance on concentric remodeling in aortic stenosis and its regression after valve replacement. J Cardiovasc Ultrasound 2016;24:201–207. https://doi.org/10.4250/jcu.2016.24.3.201

Ito H, Mizumoto T, Shomura Y, Sawada Y, Kajiyama K, Shimpo H. The impact of global left ventricular afterload on left ventricular reverse remodeling after aortic valve replacement. J Card Surg 2017;32:530–536. https://doi.org/10.1111/jocs.13190

Imanaka K, Kohmoto O, Nishimura S, Yokote Y, Kyo S. Impact of postoperative blood pressure control on regression of left ventricular mass following valve replacement for aortic stenosis. Eur J Cardiothorac Surg 2005;27:994–999. https://doi.org/10.1016/j.ejcts.2005.02.034

Gavina C, Falcao‐Pires I, Rodrigues J, Marinho B, Goncalves N, Lopes R, et al. Load independent impairment of reverse remodeling after valve replacement in hypertensive aortic stenosis patients. Int J Cardiol 2014;170:324–330. https://doi.org/10.1016/j.ijcard.2013.11.006

Borovac JA, D'Amario D, Bozic J, Glavas D. Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers. World J Cardiol 2020;12:373–408. https://doi.org/10.4330/wjc.v12.i8.373

Abdellatif M, Rainer PP, Sedej S, Kroemer G. Hallmarks of cardiovascular ageing. Nat Rev Cardiol 2023;20:754–777. https://doi.org/10.1038/s41569‐023‐00881‐3

Nakamura T, Toda K, Kuratani T, Miyagawa S, Yoshikawa Y, Fukushima S, et al. Diabetes mellitus impairs left ventricular mass regression after surgical or transcatheter aortic valve replacement for severe aortic stenosis. Heart Lung Circ 2016;25:68–74. https://doi.org/10.1016/j.hlc.2015.05.019

Falcao‐Pires I, Hamdani N, Borbely A, Gavina C, Schalkwijk CG, van der Velden J, et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011;124:1151–1159. https://doi.org/10.1161/CIRCULATIONAHA.111.025270

Einarsen E, Saeed S, Cramariuc D, Chambers JB, Midtbo H, Gerdts E. Impact of obesity on persistent left ventricular hypertrophy after aortic valve replacement for aortic stenosis. Am J Cardiol 2019;123:942–947. https://doi.org/10.1016/j.amjcard.2018.12.012

Vaduganathan M, Lee R, Beckham AJ, Andrei AC, Lapin B, Stone NJ, et al. Relation of body mass index to late survival after valvular heart surgery. Am J Cardiol 2012;110:1667–1678. https://doi.org/10.1016/j.amjcard.2012.07.041

Roberts WC, Roberts CC, Vowels TJ, Ko JM, Filardo G, Hamman BL, et al. Effect of body mass index on survival in patients having aortic valve replacement for aortic stenosis with or without concomitant coronary artery bypass grafting. Am J Cardiol 2011;108:1767–1771. https://doi.org/10.1016/j.amjcard.2011.09.010

Bruno VD, Chivasso P, Rapetto F, Guida G, Di Tommaso E, Chau HM, et al. Impact of body mass index on short‐ and long‐term outcomes after isolated first‐time surgical aortic valve replacement for aortic stenosis. J Cardiothorac Vasc Anesth 2019;33:2995–3000. https://doi.org/10.1053/j.jvca.2019.02.015

Vicente JA, Blasco IL, Perez PP, Sanchez BS, Nadal MR, Arroyo JR, et al. Impact of moderate coronary atherosclerosis on long‐term left ventricular remodeling after aortic valve replacemen. Cardiol J 2011;18:277–281. PMID: 21660917.

Biederman RW, Doyle M, Yamrozik J, Williams RB, Rathi VK, Vido D, et al. Physiologic compensation is supranormal in compensated aortic stenosis: Does it return to normal after aortic valve replacement or is it blunted by coexistent coronary artery disease? An intramyocardial magnetic resonance imaging study. Circulation 2005;112:I429–I436. https://doi.org/10.1161/CIRCULATIONAHA.104.525501

Sharma UC, Barenbrug P, Pokharel S, Dassen WR, Pinto YM, Maessen JG. Systematic review of the outcome of aortic valve replacement in patients with aortic stenosis. Ann Thorac Surg 2004;78:90–95. https://doi.org/10.1016/j.athoracsur.2004.02.020

Petrov G, Regitz‐Zagrosek V, Lehmkuhl E, Krabatsch T, Dunkel A, Dandel M, et al. Regression of myocardial hypertrophy after aortic valve replacement: Faster in women? Circulation 2010;122:S23–S28. https://doi.org/10.1161/CIRCULATIONAHA.109.927764

Gaudino M, Alessandrini F, Glieca F, Luciani N, Cellini C, Pragliola C, et al. Survival after aortic valve replacement for aortic stenosis: Does left ventricular mass regression have a clinical correlate? Eur Heart J 2005;26:51–57. https://doi.org/10.1093/eurheartj/ehi012

Gonzalez A, Ravassa S, Lopez B, Moreno MU, Beaumont J, San Jose G, et al. Myocardial remodeling in hypertension. Hypertension 2018;72:549–558. https://doi.org/10.1161/HYPERTENSIONAHA.118.11125

Knoll R, Iaccarino G, Tarone G, Hilfiker‐Kleiner D, Bauersachs J, Leite‐Moreira AF, et al.; European Society of Cardiology. Towards a re‐definition of ‘cardiac hypertrophy’ through a rational characterization of left ventricular phenotypes: A position paper of the Working Group ‘Myocardial Function’ of the ESC. Eur J Heart Fail 2011;13:811–819. https://doi.org/10.1093/eurjhf/hfr071

Diez J, Gonzalez A, Lopez B, Querejeta R. Mechanisms of disease: Pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005;2:209–216. https://doi.org/10.1038/ncpcardio0158

Visco V, Pascale AV, Virtuoso N, Mongiello F, Cinque F, Gioia R, et al. Serum uric acid and left ventricular mass in essential hypertension. Front Cardiovasc Med 2020;7:570000. https://doi.org/10.3389/fcvm.2020.570000

Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens 2015;29:1–6. https://doi.org/10.1038/jhh.2014.36

Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 2001;103:102–107. https://doi.org/10.1161/01.cir.103.1.102

Gonzalez A, Ravassa S, Beaumont J, Lopez B, Diez J. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 2011;58:1833–1843. https://doi.org/10.1016/j.jacc.2011.06.058

Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, et al. Targeting myocardial remodelling to develop novel therapies for heart failure: A position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail 2014;16:494–508. https://doi.org/10.1002/ejhf.62

Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlof B, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: Results of a randomized trial. Circulation 2004;110:552–557. https://doi.org/10.1161/01.CIR.0000137118.47943.5C

Scridon A, Balan AI. Targeting myocardial fibrosis‐a magic pill in cardiovascular medicine? Pharmaceutics 2022;14:1599. https://doi.org/10.3390/pharmaceutics14081599

Passaro F, Tocchetti CG, Spinetti G, Paudice F, Ambrosone L, Costagliola C, et al. Targeting fibrosis in the failing heart with nanoparticles. Adv Drug Deliv Rev 2021;174:461–481. https://doi.org/10.1016/j.addr.2021.05.004

de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur J Heart Fail 2019;21:272–285. https://doi.org/10.1002/ejhf.1406

Gavina C, Falcão‐Pires I, Pinho P, Manso MC, Gonçalves A, Rocha‐Gonçalves F, et al. Relevance of residual left ventricular hypertrophy after surgery for isolated aortic stenosis. Eur J Cardiothorac Surg 2016;49:952–959. https://doi.org/10.1093/ejcts/ezv240

Hatani T, Kitai T, Murai R, Kim K, Ehara N, Kobori A, et al. Associations of residual left ventricular and left atrial remodeling with clinical outcomes in patients after aortic valve replacement for severe aortic stenosis. J Cardiol 2016;68:241–247. https://doi.org/10.1016/j.jjcc.2015.09.017

Izumi C, Kitai T, Kume T, Onishi T, Yuda S, Hirata K, et al. Effect of left ventricular reverse remodeling on long‐term outcomes after aortic valve replacement. Am J Cardiol 2019;124:105–112. https://doi.org/10.1016/j.amjcard.2019.04.010

Daubert MA, White JA, Al‐Khalidi HR, Velazquez EJ, Rao SV, Crowley AL, et al. Cardiac remodeling after large ST‐elevation myocardial infarction in the current therapeutic era. Am Heart J 2020;223:87–97. https://doi.org/10.1016/j.ahj.2020.02.017

van der Bijl P, Abou R, Goedemans L, Gersh BJ, Holmes DR Jr, Ajmone Marsan N, et al. Left ventricular post‐infarct remodeling: Implications for systolic function improvement and outcomes in the modern era. JACC Heart Fail 2020;8:131–140. https://doi.org/10.1016/j.jchf.2019.08.014

Chimed S, van der Bijl P, Lustosa R, Fortuni F, Montero‐Cabezas JM, Ajmone Marsan N, et al. Functional classification of left ventricular remodelling: Prognostic relevance in myocardial infarction. ESC Heart Fail 2022;9:912–924. https://doi.org/10.1002/ehf2.13802

Olsen C, Mandawat A, Sun JL, Triana T, Chiswell K, Karra R. Recovery of left ventricular function is associated with improved outcomes in LVAD recipients. J Heart Lung Transplant 2022;41:1055–1062. https://doi.org/10.1016/j.healun.2022.03.008

Mirza KK, Szymanski MK, Schmidt T, de Jonge N, Brahmbhatt DH, Billia F, et al.; PRO‐VAD Investigators. Prognostic value of peak oxygen uptake in patients supported with left ventricular assist devices (PRO‐VAD). JACC Heart Fail 2021;9:758–767. https://doi.org/10.1016/j.jchf.2021.05.021

Topilsky Y, Hasin T, Oh JK, Borgeson DD, Boilson BA, Schirger JA, et al. Echocardiographic variables after left ventricular assist device implantation associated with adverse outcome. Circ Cardiovasc Imaging 2011;4:648–661. https://doi.org/10.1161/CIRCIMAGING.111.965335

Frigerio M, Lunati M, Pasqualucci D, Vargiu S, Foti G, Pedretti S, et al. Left ventricular ejection fraction overcrossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: Single center observational experience. Int J Cardiol 2014;172:64–71. https://doi.org/10.1016/j.ijcard.2013.12.005

Stankovic I, Belmans A, Prinz C, Ciarka A, Maria Daraban A, Kotrc M, et al. The association of volumetric response and long‐term survival after cardiac resynchronization therapy. Eur Heart J Cardiovasc Imaging 2017;18:1109–1117. https://doi.org/10.1093/ehjci/jex188

van der Bijl P, Kostyukevich MV, Khidir M, Ajmone Marsan N, Delgado V, Bax JJ. Left ventricular remodelling and change in left ventricular global longitudinal strain after cardiac resynchronization therapy: Prognostic implications. Eur Heart J Cardiovasc Imaging 2019;20:1112–1119. https://doi.org/10.1093/ehjci/jez072

Cramariuc D, Gerdts E, Segadal L. Impact of hypertension on left ventricular hypertrophy regression and exercise capacity in patients operated for aortic valve stenosis. Scand Cardiovasc J 2006;40:167–174. https://doi.org/10.1080/14017430500468161

Tao K, Sakata R, Iguro Y, Ueno T, Ueno M, Tanaka Y, et al. Abnormal Tei index predicts poor left ventricular mass regression and survival after AVR in aortic stenosis patients. J Cardiol 2009;53:240–247. https://doi.org/10.1016/j.jjcc.2008.11.014

Mhagna Z, Tasca G, Brunelli F, Cirillo M, Amaducci A, DallaTomba M, et al. Effect of the increase in valve area after aortic valve replacement with a 19‐mm aortic valve prosthesis on left ventricular mass regression in patients with pure aortic stenosis. J Cardiovasc Med (Hagerstown) 2006;7:351–355. https://doi.org/10.2459/01.JCM.0000223258.47180.9d

Puls M, Beuthner BE, Topci R, Vogelgesang A, Bleckmann A, Sitte M, et al. Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis. Eur Heart J 2020;41:1903–1914. https://doi.org/10.1093/eurheartj/ehaa033

Dobson LE, Musa TA, Uddin A, Fairbairn TA, Swoboda PP, Erhayiem B, et al. Acute reverse remodelling after transcatheter aortic valve implantation: A link between myocardial fibrosis and left ventricular mass regression. Can J Cardiol 2016;32:1411–1418. https://doi.org/10.1016/j.cjca.2016.04.009

Licker M, Cikirikcioglu M, Inan C, Cartier V, Kalangos A, Theologou T, et al. Preoperative diastolic function predicts the onset of left ventricular dysfunction following aortic valve replacement in high‐risk patients with aortic stenosis. Crit Care 2010;14:R101. https://doi.org/10.1186/cc9040

Lisi M, Henein MY, Cameli M, Ballo P, Reccia R, Bennati E, et al. Severity of aortic stenosis predicts early post‐operative normalization of left atrial size and function detected by myocardial strain. Int J Cardiol 2013;167:1450–1455. https://doi.org/10.1016/j.ijcard.2012.04.057

Benfari G, Noni M, Onorati F, Cerrito LF, Pernigo M, Vinco G, et al. Effects of aortic valve replacement on left ventricular diastolic function in patients with aortic valve stenosis. Am J Cardiol 2019;124:409–415. https://doi.org/10.1016/j.amjcard.2019.04.046

Hwang JW, Kim SM, Park SJ, Cho EJ, Kim EK, Chang SA, et al. Assessment of reverse remodeling predicted by myocardial deformation on tissue tracking in patients with severe aortic stenosis: A cardiovascular magnetic resonance imaging study. J Cardiovasc Magn Reson 2017;19:80. https://doi.org/10.1186/s12968‐017‐0392‐0

Garcia R, Villar AV, Cobo M, Llano M, Martin‐Duran R, Hurle MA, et al. Circulating levels of miR‐133a predict the regression potential of left ventricular hypertrophy after valve replacement surgery in patients with aortic stenosis. J Am Heart Assoc 2013;2:e000211. https://doi.org/10.1161/JAHA.113.000211

Ong G, Redfors B, Crowley A, Abdel‐Qadir H, Harrington A, Liu Y, et al. Evaluation of left ventricular reverse remodeling in patients with severe aortic regurgitation undergoing aortic valve replacement: Comparison between diameters and volumes. Echocardiography 2018;35:142–147. https://doi.org/10.1111/echo.13750

Iliuță L, Andronesi AG, Scafa‐Udriște A, Rădulescu B, Moldovan H, Furtunescu FL, et al. Incidence and risk factors for long‐term persistence of diastolic dysfunction after aortic valve replacement for aortic stenosis compared with aortic regurgitation. J Cardiovasc Dev Dis 2023;10:131. https://doi.org/10.3390/jcdd10030131

Paraggio L, Burzotta F, Graziani F, Aurigemma C, Romagnoli E, Pedicino D, et al. Transcatheter aortic valve implantation in pure aortic regurgitation: Hemodynamic and echocardiographic findings in bioprosthesis vs. native valve. Catheter Cardiovasc Interv 2022;99:1599–1608. https://doi.org/10.1002/ccd.30082

Fan X, Xu X, Zhang B, Lu J, Ma Y, Tang Y, et al. Long‐term outcomes after aortic valve surgery in patients with aortic regurgitation with preserved ejection fraction and left ventricular dilation. Gen Thorac Cardiovasc Surg 2023;71:51–58. https://doi.org/10.1007/s11748‐022‐01849‐9

Koga‐Ikuta A, Fukushima S, Kawamoto N, Saito T, Shimahara Y, Yajima S, et al. Reverse remodelling after aortic valve replacement for chronic aortic regurgitation. Interact Cardiovasc Thorac Surg 2021;33:10–18. https://doi.org/10.1093/icvts/ivab046

Meucci MC, Butcher SC, Galloo X, van der Velde ET, Marsan NA, Bax JJ, et al. Noninvasive left ventricular myocardial work in patients with chronic aortic regurgitation and preserved left ventricular ejection fraction. J Am Soc Echocardiogr 2022;35:703–711.e3. https://doi.org/10.1016/j.echo.2022.01.008

Zhang MK, Li LN, Xue H, Tang XJ, Sun H, Wu QY. Left ventricle reverse remodeling in chronic aortic regurgitation patients with dilated ventricle after aortic valve replacement. J Cardiothorac Surg 2022;17:8. https://doi.org/10.1186/s13019‐022‐01754‐5

Ursi R, Pesce F, Albanese M, Pavone V, Grande D, Ciccone MM, et al. Reverse cardiac remodeling after fluid balance optimization in patients with end‐stage renal disease. Hemodial Int 2022;26:345–350. https://doi.org/10.1111/hdi.13019

Hamidi S, Kojuri J, Attar A, Roozbeh J, Moaref A, Nikoo MH. The effect of kidney transplantation on speckled tracking echocardiography findings in patients on hemodialysis. J Cardiovasc Thorac Res 2018;10:90–94. https://doi.org/10.15171/jcvtr.2018.14

Burt RK, Gupta‐Burt S, Suki WN, Barcenas CG, Ferguson JJ, Van Buren CT. Reversal of left ventricular dysfunction after renal transplantation. Ann Intern Med 1989;111:635–640. https://doi.org/10.7326/0003‐4819‐111‐8‐635

Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end‐stage renal disease. J Am Coll Cardiol 2005;45:1051–1060. https://doi.org/10.1016/j.jacc.2004.11.061

Hawwa N, Shrestha K, Hammadah M, Yeo PSD, Fatica R, Tang WHW. Reverse remodeling and prognosis following kidney transplantation in contemporary patients with cardiac dysfunction. J Am Coll Cardiol 2015;66:1779–1787. https://doi.org/10.1016/j.jacc.2015.08.023

Pickup LC, Law JP, Radhakrishnan A, Price AM, Loutradis C, Smith TO, et al. Changes in left ventricular structure and function associated with renal transplantation: A systematic review and meta‐analysis. ESC Heart Fail 2021;8:2045–2057. https://doi.org/10.1002/ehf2.13283

Barbosa MF, Contti MM, de Andrade LGM, Mauricio A, Ribeiro SM, Szarf G. Feature‐tracking cardiac magnetic resonance left ventricular global longitudinal strain improves 6 months after kidney transplantation associated with reverse remodeling, not myocardial tissue characteristics. Int J Cardiovasc Imaging 2021;37:3027–3037. https://doi.org/10.1007/s10554‐021‐02284‐2

Kobayashi M, Huttin O, Schikowski J, Bozec E, Zohra L, Frimat L, et al. Cardiovascular comorbidities are the main predictors of cardiac reverse remodeling following kidney transplantation. Cardiology 2020;145:71–76. https://doi.org/10.1159/000504381

Heusch G. Myocardial stunning and hibernation revisited. Nat Rev Cardiol 2021;18:522–536. https://doi.org/10.1038/s41569‐021‐00506‐7

Howlett JG, Stebbins A, Petrie MC, Jhund PS, Castelvecchio S, Cherniavsky A, et al.; STICH Trial Investigators. CABG improves outcomes in patients with ischemic cardiomyopathy: 10‐year follow‐up of the STICH trial. JACC Heart Fail 2019;7:878–887. https://doi.org/10.1016/j.jchf.2019.04.018

Perera D, Clayton T, O'Kane PD, Greenwood JP, Weerackody R, Ryan M, et al.; REVIVED‐BCIS2 Investigators. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med 2022;387:1351–1360. https://doi.org/10.1056/NEJMoa2206606

Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al.; STICH Investigators. Coronary‐artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607–1616. https://doi.org/10.1056/NEJMoa1100356

Rohde LE, McMurray JJV. REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed. Eur Heart J 2023;44:3652–3654. https://doi.org/10.1093/eurheartj/ehad488

Kloner RA. Stunned and hibernating myocardium: Where are we nearly 4 decades later? J Am Heart Assoc 2020;9:e015502. https://doi.org/10.1161/JAHA.119.015502

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli‐Ducci C, Bueno H, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST‐segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177. https://doi.org/10.1093/eurheartj/ehx393

Bax JJ, Visser FC, Poldermans D, Elhendy A, Cornel JH, Boersma E, et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 2001;104:I314–I318. https://doi.org/10.1161/hc37t1.094853

van der Bijl P, Abou R, Goedemans L, Gersh BJ, Holmes DR Jr, Ajmone Marsan N, et al. Left ventricular remodelling after ST‐segment elevation myocardial infarction: Sex differences and prognosis. ESC Heart Fail 2020;7:474–481. https://doi.org/10.1002/ehf2.12618

Hashimoto H, Olson EN, Bassel‐Duby R. Therapeutic approaches for cardiac regeneration and repair. Nat Rev Cardiol 2018;15:585–600. https://doi.org/10.1038/s41569‐018‐0036‐6

Gabrielli L, Sitges M, Mont L. Assessing reverse remodeling in heart failure patients treated with cardiac resynchronization therapy and its impact on prognosis. Expert Rev Cardiovasc Ther 2012;10:1437–1448. https://doi.org/10.1586/erc.12.137

McAloon CJ, Theodoreson MD, Hayat S, Osman F. Cardiac resynchronization therapy and its role in the management of heart failure. Br J Hosp Med (Lond) 2017;78:312–319. https://doi.org/10.12968/hmed.2017.78.6.312

Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non‐responders to cardiac resynchronization therapy: A practical guide. Eur Heart J 2017;38:1463–1472. https://doi.org/10.1093/eurheartj/ehw270

Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al.; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD trial. JAMA 2003;289:2685–2694. https://doi.org/10.1001/jama.289.20.2685

Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003;42:1454–1459. https://doi.org/10.1016/s0735‐1097(03)01042‐8

St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al.; Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003;107:1985–1990. https://doi.org/10.1161/01.CIR.0000065226.24159.E9

Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: Quantitative doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation 2006;113:266–272. https://doi.org/10.1161/CIRCULATIONAHA.104.520817

Cimino S, Maestrini V, Cantisani D, Petronilli V, Filomena D, Gatto MC, et al. 2D/3D echocardiographic features of patients with reverse remodeling after cardiac resynchronization therapy. Echocardiography 2019;36:1475–1481. https://doi.org/10.1111/echo.14425

Chen Z, Hanson B, Sohal M, Sammut E, Jackson T, Child N, et al. Coupling of ventricular action potential duration and local strain patterns during reverse remodeling in responders and nonresponders to cardiac resynchronization therapy. Heart Rhythm 2016;13:1898–1904. https://doi.org/10.1016/j.hrthm.2016.06.014

Martens P, Nijst P, Verbrugge FH, Dupont M, Tang WHW, Mullens W. Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology. Heart Rhythm 2018;15:130–136. https://doi.org/10.1016/j.hrthm.2017.08.021

Miyagawa S, Toda K, Nakamura T, Yoshikawa Y, Fukushima S, Saito S, et al. Building a bridge to recovery: The pathophysiology of LVAD‐induced reverse modeling in heart failure. Surg Today 2016;46:149–154. https://doi.org/10.1007/s00595‐015‐1149‐8

Klotz S, Jan Danser AH, Burkhoff D. Impact of left ventricular assist device (LVAD) support on the cardiac reverse remodeling process. Prog Biophys Mol Biol 2008;97:479–496. https://doi.org/10.1016/j.pbiomolbio.2008.02.002

Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006;355:1873–1884. https://doi.org/10.1056/NEJMoa053063

Birks EJ, George RS. Molecular changes occurring during reverse remodelling following left ventricular assist device support. J Cardiovasc Transl Res 2010;3:635–642. https://doi.org/10.1007/s12265‐010‐9220‐8

Radovancevic B, Vrtovec B, Frazier OH. Left ventricular assist devices: An alternative to medical therapy for end‐stage heart failure. Curr Opin Cardiol 2003;18:210–214. https://doi.org/10.1097/00001573‐200305000‐00006

Drakos SG, Mehra MR. Clinical myocardial recovery during long‐term mechanical support in advanced heart failure: Insights into moving the field forward. J Heart Lung Transplant 2016;35:413–420. https://doi.org/10.1016/j.healun.2016.01.001

Muthiah K, Humphreys DT, Robson D, Dhital K, Spratt P, Jansz P, et al. Longitudinal structural, functional, and cellular myocardial alterations with chronic centrifugal continuous‐flow left ventricular assist device support. J Heart Lung Transplant 2017;36:722–731. https://doi.org/10.1016/j.healun.2016.05.017

Imamura T, Kinugawa K, Nitta D, Hatano M, Kinoshita O, Nawata K, et al. Advantage of pulsatility in left ventricular reverse remodeling and aortic insufficiency prevention during left ventricular assist device treatment. Circ J 2015;79:1994–1999. https://doi.org/10.1253/circj.CJ‐15‐0419

Haft J, Armstrong W, Dyke DB, Aaronson KD, Koelling TM, Farrar DJ, et al. Hemodynamic and exercise performance with pulsatile and continuous‐flow left ventricular assist devices. Circulation 2007;116:I8–I15. https://doi.org/10.1161/CIRCULATIONAHA.106.677898

Kanellakis P, Dinh TN, Agrotis A, Bobik A. CD4+CD25+Foxp3+ regulatory T cells suppress cardiac fibrosis in the hypertensive heart. J Hypertens 2011;29:1820–1828. https://doi.org/10.1097/HJH.0b013e328349c62d

Matrougui K, Abd Elmageed Z, Kassan M, Choi S, Nair D, Gonzalez‐Villalobos RA, et al. Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol 2011;178:434–441. https://doi.org/10.1016/j.ajpath.2010.11.034

Rieckmann M, Delgobo M, Gaal C, Büchner L, Steinau P, Reshef D, et al. Myocardial infarction triggers cardioprotective antigen‐specific T helper cell responses. J Clin Invest 2019;129:4922–4936. https://doi.org/10.1172/JCI123859

Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, et al. Phosphodiesterase 9A controls nitric‐oxide‐independent cGMP and hypertrophic heart disease. Nature 2015;519:472–476. https://doi.org/10.1038/nature14332

Gargalovic P, Wong P, Onorato J, Finlay H, Wang T, Yan M, et al. In vitro and in vivo evaluation of a small‐molecule APJ (apelin receptor) agonist, BMS‐986224, as a potential treatment for heart failure. Circ Heart Fail 2021;14:e007351. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007351

Kim GJ, Jung H, Lee E, Chung SW. Histone deacetylase inhibitor, mocetinostat, regulates cardiac remodelling and renin‐angiotensin system activity in rats with transverse aortic constriction‐induced pressure overload cardiac hypertrophy. Rev Cardiovasc Med 2021;22:1037–1045. https://doi.org/10.31083/j.rcm2203113

Dey S, DeMazumder D, Sidor A, Foster DB, O'Rourke B. Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failure. Circ Res 2018;123:356–371. https://doi.org/10.1161/CIRCRESAHA.118.312708

Abdellatif M, Trummer‐Herbst V, Koser F, Durand S, Adao R, Vasques‐Novoa F, et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci Transl Med 2021;13:eabd7064. https://doi.org/10.1126/scitranslmed.abd7064

Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, et al. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med 2017;9:eaah5084. https://doi.org/10.1126/scitranslmed.aah5084

Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial‐to‐mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952–961. https://doi.org/10.1038/nm1613

Seropian IM, Cerliani JP, Toldo S, Van Tassell BW, Ilarregui JM, González GE, et al. Galectin‐1 controls cardiac inflammation and ventricular remodeling during acute myocardial infarction. Am J Pathol 2013;182:29–40. https://doi.org/10.1016/j.ajpath.2012.09.022

Rech L, Abdellatif M, Pottler M, Stangl V, Mabotuwana N, Hardy S, et al. Small molecule STING inhibition improves myocardial infarction remodeling. Life Sci 2022;291:120263. https://doi.org/10.1016/j.lfs.2021.120263

Marchetti C, Toldo S, Chojnacki J, Mezzaroma E, Liu K, Salloum FN, et al. Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse. J Cardiovasc Pharmacol 2015;66:1–8. https://doi.org/10.1097/FJC.0000000000000247

Li J, Cai SX, He Q, Zhang H, Friedberg D, Wang F, et al. Intravenous miR‐144 reduces left ventricular remodeling after myocardial infarction. Basic Res Cardiol 2018;113:36. https://doi.org/10.1007/s00395‐018‐0694‐x

Traverse JH, Swingen CM, Henry TD, Fox J, Wang YL, Chavez IJ, et al. NHLBI‐sponsored randomized trial of postconditioning during primary percutaneous coronary intervention for ST‐elevation myocardial infarction. Circ Res 2019;124:769–778. https://doi.org/10.1161/CIRCRESAHA.118.314060

Luz A, Santos M, Magalhães R, Silveira J, Cabral S, Dias V, et al. Lack of benefit of ischemic postconditioning after routine thrombus aspiration during reperfusion: Immediate and midterm results. J Cardiovasc Pharmacol Ther 2015;20:523–531. https://doi.org/10.1177/1074248415578171

Stiermaier T, Jensen JO, Rommel KP, de Waha‐Thiele S, Fuernau G, Desch S, et al. Combined intrahospital remote ischemic perconditioning and postconditioning improves clinical outcome in ST‐elevation myocardial infarction. Circ Res 2019;124:1482–1491. https://doi.org/10.1161/CIRCRESAHA.118.314500

Garcia S, Henry TD, Wang YL, Chavez IJ, Pedersen WR, Lesser JR, et al. Long‐term follow‐up of patients undergoing postconditioning during ST‐elevation myocardial infarction. J Cardiovasc Transl Res 2011;4:92–98. https://doi.org/10.1007/s12265‐010‐9252‐0

Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Clemmensen P, et al.; Third Danish Study of Optimal Acute Treatment of Patients With ST Elevation Myocardial Infarction–Ischemic Postconditioning (DANAMI‐3–iPOST) Investigators. Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST‐segment elevation myocardial infarction: A randomized clinical trial. JAMA Cardiol 2017;2:490–497. https://doi.org/10.1001/jamacardio.2017.0022

Lønborg J, Holmvang L, Kelbæk H, Vejlstrup N, Jørgensen E, Helqvist S, et al. ST‐segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonance. Am Heart J 2010;160:1085–1091. https://doi.org/10.1016/j.ahj.2010.09.026

Thuny F, Lairez O, Roubille F, Mewton N, Rioufol G, Sportouch C, et al. Post‐conditioning reduces infarct size and edema in patients with ST‐segment elevation myocardial infarction. J Am Coll Cardiol 2012;59:2175–2181. https://doi.org/10.1016/j.jacc.2012.03.026

Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol 2006;19:367–375. https://doi.org/10.1111/j.1540‐8183.2006.00191.x

Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting CC, Alexanian M, et al. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med 2017;9:eaai9118. https://doi.org/10.1126/scitranslmed.aai9118

Batkai S, Genschel C, Viereck J, Rump S, Bar C, Borchert T, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur Heart J 2021;42:192–201. https://doi.org/10.1093/eurheartj/ehaa791

Taubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, et al. Novel antisense therapy targeting microRNA‐132 in patients with heart failure: Results of a first‐in‐human Phase 1b randomized, double‐blind, placebo‐controlled study. Eur Heart J 2021;42:178–188. https://doi.org/10.1093/eurheartj/ehaa898

Foinquinos A, Batkai S, Genschel C, Viereck J, Rump S, Gyongyosi M, et al. Preclinical development of a miR‐132 inhibitor for heart failure treatment. Nat Commun 2020;11:633. https://doi.org/10.1038/s41467‐020‐14349‐2

Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, et al. A Phase II, randomized, double‐blind, multicenter, based on standard therapy, placebo‐controlled study of the efficacy and safety of recombinant human neuregulin‐1 in patients with chronic heart failure. J Am Coll Cardiol 2010;55:1907–1914. https://doi.org/10.1016/j.jacc.2009.12.044

Cacciapuoti M, Johnson B, Kapdia A, Powell S, Gallicano GI. The role of neuregulin and stem cells as therapy post‐myocardial infarction. Stem Cells Dev 2020;29:1266–1274. https://doi.org/10.1089/scd.2020.0099

Chen L, Chen CX, Gan XT, Beier N, Scholz W, Karmazyn M. Inhibition and reversal of myocardial infarction‐induced hypertrophy and heart failure by NHE‐1 inhibition. Am J Physiol Heart Circ Physiol 2004;286:H381–H387. https://doi.org/10.1152/ajpheart.00602.2003

Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, et al. AAV6.β ARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013;34:1437–1447. https://doi.org/10.1093/eurheartj/ehr447

Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, et al. Cardiac AAV9‐S100A1 gene therapy rescues post‐ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011;3:92ra64. https://doi.org/10.1126/scitranslmed.3002097

Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Res Cardiol 2014;109:421. https://doi.org/10.1007/s00395‐014‐0421‐1

Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, et al. Cardiac myosin activation: A potential therapeutic approach for systolic heart failure. Science 2011;331:1439–1443. https://doi.org/10.1126/science.1200113

Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF, Cleland JG, et al.; COSMIC‐HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC‐HF): A phase 2, pharmacokinetic, randomised, placebo‐controlled trial. Lancet 2016;388:2895–2903. https://doi.org/10.1016/S0140‐6736(16)32049‐9

Voors AA, Tamby JF, Cleland JG, Koren M, Forgosh LB, Gupta D, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: Experimental data and clinical results from a phase 2a trial. Eur J Heart Fail 2020;22:1649–1658. https://doi.org/10.1002/ejhf.1933

Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A small‐molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 2016;351:617–621. https://doi.org/10.1126/science.aad3456

Sharpe AN, Oldach MS, Kaplan JL, Rivas V, Kovacs SL, Hwee DT, et al. Pharmacokinetics of a single dose of aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model. J Vet Pharmacol Ther 2023;46:52–61. https://doi.org/10.1111/jvp.13103

Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al.; REDWOOD‐HCM Steering Committee and Investigators. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2023;81:34–45. https://doi.org/10.1016/j.jacc.2022.10.020

Gramlich M, Pane LS, Zhou Q, Chen Z, Murgia M, Schotterl S, et al. Antisense‐mediated exon skipping: A therapeutic strategy for titin‐based dilated cardiomyopathy. EMBO Mol Med 2015;7:562–576. https://doi.org/10.15252/emmm.201505047

Kraft L, Erdenesukh T, Sauter M, Tschöpe C, Klingel K. Blocking the IL‐1β signalling pathway prevents chronic viral myocarditis and cardiac remodeling. Basic Res Cardiol 2019;114:11. https://doi.org/10.1007/s00395‐019‐0719‐0

Castelvecchio S, Careri G, Ambrogi F, Camporeale A, Menicanti L, Secchi F, et al. Myocardial scar location as detected by cardiac magnetic resonance is associated with the outcome in heart failure patients undergoing surgical ventricular reconstruction. Eur J Cardiothorac Surg 2018;53:143–149. https://doi.org/10.1093/ejcts/ezx197

Garber L, McAndrew TC, Chung ES, Stancak B, Svendsen JH, Monteiro J, et al. Predictors of left ventricular remodeling after myocardial infarction in patients with a patent infarct related coronary artery after percutaneous coronary intervention (from the Post‐Myocardial Infarction Remodeling Prevention Therapy [PRomPT] trial). Am J Cardiol 2018;121:1293–1298. https://doi.org/10.1016/j.amjcard.2018.02.007

Ben Driss A, Ben Driss Lepage C, Sfaxi A, Hakim M, Elhadad S, Tabet JY, et al. Strain predicts left ventricular functional recovery after acute myocardial infarction with systolic dysfunction. Int J Cardiol 2020;307:1–7. https://doi.org/10.1016/j.ijcard.2020.02.039

Reindl M, Tiller C, Holzknecht M, Lechner I, Eisner D, Riepl L, et al. Global longitudinal strain by feature tracking for optimized prediction of adverse remodeling after ST‐elevation myocardial infarction. Clin Res Cardiol 2021;110:61–71. https://doi.org/10.1007/s00392‐020‐01649‐2

Pezel T, Besseyre des Horts T, Schaaf M, Croisille P, Biere L, Garcia‐Dorado D, et al. Predictive value of early cardiac magnetic resonance imaging functional and geometric indexes for adverse left ventricular remodelling in patients with anterior ST‐segment elevation myocardial infarction: A report from the CIRCUS study. Arch Cardiovasc Dis 2020;113:710–720. https://doi.org/10.1016/j.acvd.2020.05.024

Minana G, Nunez J, Bayes‐Genis A, Revuelta‐Lopez E, Rios‐Navarro C, Nunez E, et al. ST2 and left ventricular remodeling after ST‐segment elevation myocardial infarction: A cardiac magnetic resonance study. Int J Cardiol 2018;270:336–342. https://doi.org/10.1016/j.ijcard.2018.06.073

Andrejic OM, Vucic RM, Pavlovic M, McClements L, Stokanovic D, Jevtovic‐Stoimenov T, et al. Association between galectin‐3 levels within central and peripheral venous blood, and adverse left ventricular remodelling after first acute myocardial infarction. Sci Rep 2019;9:13145. https://doi.org/10.1038/s41598‐019‐49511‐4

de Gonzalo‐Calvo D, Cediel G, Bar C, Nunez J, Revuelta‐Lopez E, Gavara J, et al. Circulating miR‐1254 predicts ventricular remodeling in patients with ST‐segment‐elevation myocardial infarction: A cardiovascular magnetic resonance study. Sci Rep 2018;8:15115. https://doi.org/10.1038/s41598‐018‐33491‐y

Dudek M, Kałużna‐Oleksy M, Migaj J, Sawczak F, Krysztofiak H, Lesiak M, et al. sST2 and heart failure‐clinical utility and prognosis. J Clin Med 2023;12:3136. https://doi.org/10.3390/jcm12093136

Lupón J, Gaggin HK, de Antonio M, Domingo M, Galán A, Zamora E, et al. Biomarker‐assist score for reverse remodeling prediction in heart failure: The ST2‐R2 score. Int J Cardiol 2015;184:337–343. https://doi.org/10.1016/j.ijcard.2015.02.019

Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, et al.; ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020;382:1395–1407. https://doi.org/10.1056/NEJMoa1915922

Giallauria F, Cirillo P, Lucci R, Pacileo M, De Lorenzo A, D'Agostino M, et al. Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: Favourable effects of exercise training and predictive role of N‐terminal pro‐brain natriuretic peptide. Eur J Cardiovasc Prev Rehabil 2008;15:113–118. https://doi.org/10.1097/HJR.0b013e3282f00990

McGregor G, Gaze D, Oxborough D, O'Driscoll J, Shave R. Reverse left ventricular remodeling: Effect of cardiac rehabilitation exercise training in myocardial infarction patients with preserved ejection fraction. Eur J Phys Rehabil Med 2016;52:370–378. PMID: 26530212.

Taylor RS, Dalal HM, Zwisler AD. Cardiac rehabilitation for heart failure: ‘Cinderella’ or evidence‐based pillar of care? Eur Heart J 2023;44:1511–1518. https://doi.org/10.1093/eurheartj/ehad118

Haykowsky M, Scott J, Esch B, Schopflocher D, Myers J, Paterson I, et al. A meta‐analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction: Start early and go longer for greatest exercise benefits on remodeling. Trials 2011;12:92. https://doi.org/10.1186/1745‐6215‐12‐92

Wang L, Gao K, Wang D. Exercise training has restorative potential on myocardial energy metabolism in rats with chronic heart failure. Iran J Basic Med Sci 2018;21:818–823. https://doi.org/10.22038/IJBMS.2018.29294.7076

Godfrey R, Theologou T, Dellegrottaglie S, Binukrishnan S, Wright J, Whyte G, et al. The effect of high‐intensity aerobic interval training on postinfarction left ventricular remodelling. BMJ Case Rep 2013;2013:bcr2012007668. https://doi.org/10.1136/bcr‐2012‐007668

D'Andrea A, Carbone A, Ilardi F, Pacileo M, Savarese C, Sperlongano S, et al. Effects of high intensity interval training rehabilitation protocol after an acute coronary syndrome on myocardial work and atrial strain. Medicina (Kaunas) 2022;58:453. https://doi.org/10.3390/medicina58030453

Eser P, Trachsel LD, Marcin T, Herzig D, Freiburghaus I, De Marchi S, et al. Short‐ and long‐term effects of high‐intensity interval training vs. moderate‐intensity continuous training on left ventricular remodeling in patients early after ST‐segment elevation myocardial infarction – the HIIT‐EARLY randomized controlled trial. Front Cardiovasc Med 2022;9:869501. https://doi.org/10.3389/fcvm.2022.869501

Otsuka Y, Takaki H, Okano Y, Satoh T, Aihara N, Matsumoto T, et al. Exercise training without ventricular remodeling in patients with moderate to severe left ventricular dysfunction early after acute myocardial infarction. Int J Cardiol 2003;87:237–244. https://doi.org/10.1016/s0167‐5273(02)00251‐6

Dubach P, Myers J, Dziekan G, Goebbels U, Reinhart W, Vogt P, et al. Effect of exercise training on myocardial remodeling in patients with reduced left ventricular function after myocardial infarction: Application of magnetic resonance imaging. Circulation 1997;95:2060–2067. https://doi.org/10.1161/01.CIR.95.8.2060

Elshazly A, Hasan RL, Saleh MA, Ibrahim AS, Khorshid H. Impact of exercise training on myocardial contractile functions assessed by cardiac magnetic resonance in post‐myocardial infarction patients. Egypt Heart J 2022;74:51. https://doi.org/10.1186/s43044‐022‐00288‐4

Chen MG, Liang X, Kong L, Wang J, Wang F, Hu X, et al. Effect of Baduanjin sequential therapy on the quality of life and cardiac function in patients with AMI after PCI: A randomized controlled trial. Evid Based Complement Alternat Med 2020;2020:8171549. https://doi.org/10.1155/2020/8171549

Rognmo Ø, Moholdt T, Bakken H, Hole T, Mølstad P, Myhr NE, et al. Cardiovascular risk of high‐ versus moderate‐intensity aerobic exercise in coronary heart disease patients. Circulation 2012;126:1436–1440. https://doi.org/10.1161/CIRCULATIONAHA.112.123117

Cannistra LB, Davidoff R, Picard MH, Balady GJ. Moderate‐high intensity exercise training after myocardial infarction: Effect on left ventricular remodeling. J Cardiopulm Rehabil 1999;19:373–380. https://doi.org/10.1097/00008483‐199911000‐00009

Gil‐Cruz C, Perez‐Shibayama C, De Martin A, Ronchi F, van der Borght K, Niederer R, et al. Microbiota‐derived peptide mimics drive lethal inflammatory cardiomyopathy. Science 2019;366:881–886. https://doi.org/10.1126/science.aav3487

Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. Nat Rev Cardiol 2021;18:169–193. https://doi.org/10.1038/s41569‐020‐00435‐x

Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: An expert consensus document. Circ Heart Fail 2020;13:e007405. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007405

Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis. Eur Heart J 2020;41:1733–1743. https://doi.org/10.1093/eurheartj/ehaa051

Escher F, Kühl U, Lassner D, Poller W, Westermann D, Pieske B, et al. Long‐term outcome of patients with virus‐negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol 2016;105:1011–1020. https://doi.org/10.1007/s00392‐016‐1011‐z

de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, et al. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail 2022;24:406–420. https://doi.org/10.1002/ejhf.2414

Yogasundaram H, Alhumaid W, Dzwiniel T, Christian S, Oudit GY. Cardiomyopathies and genetic testing in heart failure: Role in defining phenotype‐targeted approaches and management. Can J Cardiol 2021;37:547–559. https://doi.org/10.1016/j.cjca.2021.01.016

Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 2020;141:1872–1884. https://doi.org/10.1161/CIRCULATIONAHA.119.044934

Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, et al. Valsartan in early‐stage hypertrophic cardiomyopathy: A randomized phase 2 trial. Nat Med 2021;27:1818–1824. https://doi.org/10.1038/s41591‐021‐01505‐4

Ho CY, Lakdawala NK, Cirino AL, Lipshultz SE, Sparks E, Abbasi SA, et al. Diltiazem treatment for pre‐clinical hypertrophic cardiomyopathy sarcomere mutation carriers: A pilot randomized trial to modify disease expression. JACC Heart Fail 2015;3:180–188. https://doi.org/10.1016/j.jchf.2014.08.003

Olivotto I, Oreziak A, Barriales‐Villa R, Abraham TP, Masri A, Garcia‐Pavia P, et al.; EXPLORER‐HCM Study Investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER‐HCM): A randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet 2020;396:759–769. https://doi.org/10.1016/S0140‐6736(20)31792‐X

Helms AS, Thompson AD, Day SM. Translation of new and emerging therapies for genetic cardiomyopathies. JACC Basic Transl Sci 2022;7:70–83. https://doi.org/10.1016/j.jacbts.2021.07.012

Schlossarek S, Mearini G, Carrier L. Cardiac myosin‐binding protein C in hypertrophic cardiomyopathy: Mechanisms and therapeutic opportunities. J Mol Cell Cardiol 2011;50:613–620. https://doi.org/10.1016/j.yjmcc.2011.01.014

Fomin A, Gartner A, Cyganek L, Tiburcy M, Tuleta I, Wellers L, et al. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations. Sci Transl Med 2021;13:eabd3079. https://doi.org/10.1126/scitranslmed.abd3079

Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:1776–1782. https://doi.org/10.1016/S0735‐1097(02)03009‐7

Witjas‐Paalberends ER, Guclu A, Germans T, Knaapen P, Harms HJ, Vermeer AM, et al. Gene‐specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res 2014;103:248–257. https://doi.org/10.1093/cvr/cvu127

Lehman SJ, Crocini C, Leinwand LA. Targeting the sarcomere in inherited cardiomyopathies. Nat Rev Cardiol 2022;19:353–363. https://doi.org/10.1038/s41569‐022‐00682‐0

Singh T, Khan H, Gamble DT, Scally C, Newby DE, Dawson D. Takotsubo syndrome: Pathophysiology, emerging concepts, and clinical implications. Circulation 2022;145:1002–1019. https://doi.org/10.1161/CIRCULATIONAHA.121.055854

Pattisapu VK, Hao H, Liu Y, Nguyen TT, Hoang A, Bairey Merz CN, et al. Sex‐ and age‐based temporal trends in takotsubo syndrome incidence in the United States. J Am Heart Assoc 2021;10:e019583. https://doi.org/10.1161/JAHA.120.019583

Eitel I, von Knobelsdorff‐Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 2011;306:277–286. https://doi.org/10.1001/jama.2011.992

Scally C, Rudd A, Mezincescu A, Wilson H, Srivanasan J, Horgan G, et al. Persistent long‐term structural, functional, and metabolic changes after stress‐induced (takotsubo) cardiomyopathy. Circulation 2018;137:1039–1048. https://doi.org/10.1161/CIRCULATIONAHA.117.031841

Scally C, Abbas H, Ahearn T, Srinivasan J, Mezincescu A, Rudd A, et al. Myocardial and systemic inflammation in acute stress‐induced (takotsubo) cardiomyopathy. Circulation 2019;139:1581–1592. https://doi.org/10.1161/CIRCULATIONAHA.118.037975

Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 2015;373:929–938. https://doi.org/10.1056/NEJMoa1406761

Tornvall P, Collste O, Ehrenborg E, Järnbert‐Petterson H. A case‐control study of risk markers and mortality in takotsubo stress cardiomyopathy. J Am Coll Cardiol 2016;67:1931–1936. https://doi.org/10.1016/j.jacc.2016.02.029

O'Brien PJ, Ianuzzo CD, Moe GW, Stopps TP, Armstrong PW. Rapid ventricular pacing of dogs to heart failure: Biochemical and physiological studies. Can J Physiol Pharmacol 1990;68:34–39. https://doi.org/10.1139/y90‐004

Tseng CC, Ramjankhan FZ, de Jonge N, Chamuleau SA. Advanced strategies for end‐stage heart failure: Combining regenerative approaches with LVAD, a new horizon? Front Surg 2015;2:10. https://doi.org/10.3389/fsurg.2015.00010

Guo Z, Liu X, Liu C, Yang J, Cheng X, Chen Y, et al. Heart failure duration combined with left atrial dimension predicts super‐response and long‐term prognosis in patients with cardiac resynchronization therapy implantation. Biomed Res Int 2019;2019:2983752. https://doi.org/10.1155/2019/2983752

Jin H, Gu M, Hua W, Fan XH, Niu HX, Ding LG, et al. Predictors of super‐response to cardiac resynchronization therapy: The significance of heart failure medication, pre‐implant left ventricular geometry and high percentage of biventricular pacing. J Geriatr Cardiol 2017;14:737–742. https://doi.org/10.11909/j.issn.1671‐5411.2017.12.003

Kloosterman M, Damman K, Van Veldhuisen DJ, Rienstra M, Maass AH. The importance of myocardial contractile reserve in predicting response to cardiac resynchronization therapy. Eur J Heart Fail 2017;19:862–869. https://doi.org/10.1002/ejhf.768

Guo Z, Liu X, Cheng X, Liu C, Li P, He Y, et al. Combination of left ventricular end‐diastolic diameter and QRS duration strongly predicts good response to and prognosis of cardiac resynchronization therapy. Cardiol Res Pract 2020;2020:1257578. https://doi.org/10.1155/2020/1257578

Ghani A, Delnoy P, Adiyaman A, Ottervanger JP, Ramdat Misier AR, Smit JJJ, et al. Predictors and long‐term outcome of super‐responders to cardiac resynchronization therapy. Clin Cardiol 2017;40:292–299. https://doi.org/10.1002/clc.22658

Oka T, Inoue K, Tanaka K, Toyoshima Y, Isshiki T, Kimura T, et al. Duration of reverse remodeling response to cardiac resynchronization therapy: Rates, predictors, and clinical outcomes. Int J Cardiol 2017;243:340–346. https://doi.org/10.1016/j.ijcard.2017.05.058

Yokoyama H, Shishido K, Tobita K, Moriyama N, Murakami M, Saito S. Impact of age on mid‐term clinical outcomes and left ventricular reverse remodeling after cardiac resynchronization therapy. J Cardiol 2021;77:254–262. https://doi.org/10.1016/j.jjcc.2020.09.004

Martens P, Dupont M, Dauw J, Nijst P, Herbots L, Dendale P, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy‐the IRON‐CRT trial. Eur Heart J 2021;42:4905–4914. https://doi.org/10.1093/eurheartj/ehab411

Schiedat F, Schöne D, Aweimer A, Bösche L, Ewers A, Gotzmann M, et al. Multipoint left ventricular pacing with large anatomical separation improves reverse remodeling and response to cardiac resynchronization therapy in responders and non‐responders to conventional biventricular pacing. Clin Res Cardiol 2020;109:183–193. https://doi.org/10.1007/s00392‐019‐01499‐7

Pappone C, Ćalović Ž, Vicedomini G, Cuko A, McSpadden LC, Ryu K, et al. Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: Twelve‐month follow‐up study. Heart Rhythm 2015;12:1250–1258. https://doi.org/10.1016/j.hrthm.2015.02.008

Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His‐optimized cardiac resynchronization therapy to maximize electrical resynchronization: A feasibility study. Circ Arrhythm Electrophysiol 2019;12:e006934. https://doi.org/10.1161/CIRCEP.118.006934

Liang Y, Wang J, Gong X, Lu H, Yu Z, Zhang L, et al. Left bundle branch pacing versus biventricular pacing for acute cardiac resynchronization in patients with heart failure. Circ Arrhythm Electrophysiol 2022;15:e011181. https://doi.org/10.1161/CIRCEP.122.011181

Zweerink A, Zubarev S, Bakelants E, Potyagaylo D, Stettler C, Chmelevsky M, et al. His‐optimized cardiac resynchronization therapy with ventricular fusion pacing for electrical resynchronization in heart failure. JACC Clin Electrophysiol 2021;7:881–892. https://doi.org/10.1016/j.jacep.2020.11.029

Saito S, Matsumiya G, Sakaguchi T, Miyagawa S, Yamauchi T, Kuratani T, et al. Cardiac fibrosis and cellular hypertrophy decrease the degree of reverse remodeling and improvement in cardiac function during left ventricular assist. J Heart Lung Transplant 2010;29:672–679. https://doi.org/10.1016/j.healun.2010.01.007

Birks EJ. Molecular changes after left ventricular assist device support for heart failure. Circ Res 2013;113:777–791. https://doi.org/10.1161/CIRCRESAHA.113.301413

Bruggink AH, van Oosterhout MF, de Jonge N, Ivangh B, van Kuik J, Voorbij RH, et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006;25:1091–1098. https://doi.org/10.1016/j.healun.2006.05.011

Klotz S, Foronjy RF, Dickstein ML, Gu A, Garrelds IM, Danser AH, et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross‐linking and myocardial stiffness. Circulation 2005;112:364–374. https://doi.org/10.1161/CIRCULATIONAHA.104.515106

Pan S, Aksut B, Wever‐Pinzon OE, Rao SD, Levin AP, Garan AR, et al. Incidence and predictors of myocardial recovery on long‐term left ventricular assist device support: Results from the United Network for Organ Sharing database. J Heart Lung Transplant 2015;34:1624–1629. https://doi.org/10.1016/j.healun.2015.08.004

Topkara VK, Garan AR, Fine B, Godier‐Furnemont AF, Breskin A, Cagliostro B, et al. Myocardial recovery in patients receiving contemporary left ventricular assist devices: Results from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Circ Heart Fail 2016;9:e003157. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003157

Wever‐Pinzon O, Drakos SG, McKellar SH, Horne BD, Caine WT, Kfoury AG, et al. Cardiac recovery during long‐term left ventricular assist device support. J Am Coll Cardiol 2016;68:1540–1553. https://doi.org/10.1016/j.jacc.2016.07.743

Diakos NA, Taleb I, Kyriakopoulos CP, Shah KS, Javan H, Richins TJ, et al. Circulating and myocardial cytokines predict cardiac structural and functional improvement in patients with heart failure undergoing mechanical circulatory support. J Am Heart Assoc 2021;10:e020238. https://doi.org/10.1161/JAHA.120.020238

Fournier A, Gregoire I, el Esper N, Lalau JD, Westeel PF, Makdassi R, et al. Atrial natriuretic factor in pregnancy and pregnancy‐induced hypertension. Can J Physiol Pharmacol 1991;69:1601–1608. https://doi.org/10.1139/y91‐237

Elvan‐Taspinar A, Franx A, Bots ML, Koomans HA, Bruinse HW. Arterial stiffness and fetal growth in normotensive pregnancy. Am J Hypertens 2005;18:337–341. https://doi.org/10.1016/j.amjhyper.2004.10.020

Abbas AE, Lester SJ, Connolly H. Pregnancy and the cardiovascular system. Int J Cardiol 2005;98:179–189. https://doi.org/10.1016/j.ijcard.2003.10.028

Bello NA, Bairey Merz CN, Brown H, Davis MB, Dickert NW, El Hajj SC, et al. Diagnostic cardiovascular imaging and therapeutic strategies in pregnancy: JACC focus seminar 4/5. J Am Coll Cardiol 2021;77:1813–1822. https://doi.org/10.1016/j.jacc.2021.01.056

Meah VL, Cockcroft JR, Backx K, Shave R, Stohr EJ. Cardiac output and related haemodynamics during pregnancy: A series of meta‐analyses. Heart 2016;102:518–526. https://doi.org/10.1136/heartjnl‐2015‐308476

De Haas S, Ghossein‐Doha C, Geerts L, van Kuijk SMJ, van Drongelen J, Spaanderman MEA. Cardiac remodeling in normotensive pregnancy and in pregnancy complicated by hypertension: Systematic review and meta‐analysis. Ultrasound Obstet Gynecol 2017;50:683–696. https://doi.org/10.1002/uog.17410

Stewart RD, Nelson DB, Matulevicius SA, Morgan JL, McIntire DD, Drazner MH, et al. Cardiac magnetic resonance imaging to assess the impact of maternal habitus on cardiac remodeling during pregnancy. Am J Obstet Gynecol 2016;214:640.e1–640.e6. https://doi.org/10.1016/j.ajog.2015.11.014

Eghbali M, Wang Y, Toro L, Stefani E. Heart hypertrophy during pregnancy: A better functioning heart? Trends Cardiovasc Med 2006;16:285–291. https://doi.org/10.1016/j.tcm.2006.07.001

Parrott ME, Aljrbi E, Biederman DL, Montalvo RN, Barth JL, LaVoie HA. Maternal cardiac messenger RNA expression of extracellular matrix proteins in mice during pregnancy and the postpartum period. Exp Biol Med (Maywood) 2018;243:1220–1232. https://doi.org/10.1177/1535370218818457

Virgen‐Ortiz A, Limón‐Miranda S, Salazar‐Enríquez DG, Melnikov V, Sánchez‐Pastor EA, Castro‐Rodríguez EM. Matrix metalloproteinases system and types of fibrosis in rat heart during late pregnancy and postpartum. Medicina (Kaunas) 2019;55:199. https://doi.org/10.3390/medicina55050199

Limon‐Miranda S, Salazar‐Enriquez DG, Muñiz J, Ramirez‐Archila MV, Sanchez‐Pastor EA, Andrade F, et al. Pregnancy differentially regulates the collagens types I and III in left ventricle from rat heart. Biomed Res Int 2014;2014:984785. https://doi.org/10.1155/2014/984785

Tasar O, Kocabay G, Karagoz A, Kalayci Karabay A, Karabay CY, Kalkan S, et al. Evaluation of left atrial functions by 2‐dimensional speckle‐tracking echocardiography during healthy pregnancy. J Ultrasound Med 2019;38:2981–2988. https://doi.org/10.1002/jum.15004

Cong J, Fan T, Yang X, Squires JW, Cheng G, Zhang L, et al. Structural and functional changes in maternal left ventricle during pregnancy: A three‐dimensional speckle‐tracking echocardiography study. Cardiovasc Ultrasound 2015;13:6. https://doi.org/10.1186/1476‐7120‐13‐6

Ferreira AF, Azevedo MJ, Morais J, Trindade F, Saraiva F, Diaz SO, et al. Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling. Am J Physiol Heart Circ Physiol 2023;325:H774–H789. https://doi.org/10.1152/ajpheart.00200.2023

Kimura Y, Kato T, Miyata H, Sasaki I, Minamino‐Muta E, Nagasawa Y, et al. Factors associated with increased levels of brain natriuretic peptide and cardiac troponin I during the peripartum period. PLoS One 2019;14:e0211982. https://doi.org/10.1371/journal.pone.0211982

Umazume T, Yamada T, Yamada S, Ishikawa S, Furuta I, Iwano H, et al. Morphofunctional cardiac changes in pregnant women: Associations with biomarkers. Open Heart 2018;5:e000850. https://doi.org/10.1136/openhrt‐2018‐000850

Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H, et al. Association between hypertensive disorders of pregnancy and later risk of cardiomyopathy. JAMA 2016;315:1026–1033. https://doi.org/10.1001/jama.2016.1869

Umazume T, Yamada S, Yamada T, Ishikawa S, Furuta I, Iwano H, et al. Association of peripartum troponin I levels with left ventricular relaxation in women with hypertensive disorders of pregnancy. Open Heart 2018;5:e000829. https://doi.org/10.1136/openhrt‐2018‐000829

Ying W, Catov JM, Ouyang P. Hypertensive disorders of pregnancy and future maternal cardiovascular risk. J Am Heart Assoc 2018;7:e009382. https://doi.org/10.1161/JAHA.118.009382

Scantlebury DC, Kane GC, Wiste HJ, Bailey KR, Turner ST, Arnett DK, et al. Left ventricular hypertrophy after hypertensive pregnancy disorders. Heart 2015;101:1584–1590. https://doi.org/10.1136/heartjnl‐2015‐308098

Regitz‐Zagrosek V, Roos‐Hesselink JW, Bauersachs J, Blomström‐Lundqvist C, Cífková R, De Bonis M, et al.; Group ESCSD. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: The Task Force for the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2018;39:3165–3241. https://doi.org/10.1093/eurheartj/ehy340

Dennis AT, Castro JM, Ong M, Carr C. Haemodynamics in obese pregnant women. Int J Obstet Anesth 2012;21:129–134. https://doi.org/10.1016/j.ijoa.2011.11.007

Veille JC, Hanson R. Obesity, pregnancy, and left ventricular functioning during the third trimester. Am J Obstet Gynecol 1994;171:980–983. https://doi.org/10.1016/0002‐9378(94)90018‐3

Buddeberg BS, Sharma R, O'Driscoll JM, Kaelin Agten A, Khalil A, Thilaganathan B. Cardiac maladaptation in obese pregnant women at term. Ultrasound Obstet Gynecol 2019;54:344–349. https://doi.org/10.1002/uog.20170

Castleman JS, Ganapathy R, Taki F, Lip GY, Steeds RP, Kotecha D. Echocardiographic structure and function in hypertensive disorders of pregnancy: A systematic review. Circ Cardiovasc Imaging 2016;9:e004888. https://doi.org/10.1161/CIRCIMAGING.116.004888

Mesquita RF, Reis M, Beppler AP, Bellinazzi VR, Mattos SS, Lima‐Filho JL, et al. Onset of hypertension during pregnancy is associated with long‐term worse blood pressure control and adverse cardiac remodeling. J Am Soc Hypertens 2014;8:827–831. https://doi.org/10.1016/j.jash.2014.09.006

Yuan L, Duan Y, Cao T. Echocardiographic study of cardiac morphological and functional changes before and after parturition in pregnancy‐induced hypertension. Echocardiography 2006;23:177–182. https://doi.org/10.1111/j.1540‐8175.2006.00203.x

Vasapollo B, Novelli GP, Gagliardi G, Farsetti D, Valensise H. Pregnancy complications in chronic hypertensive patients are linked to pre‐pregnancy maternal cardiac function and structure. Am J Obstet Gynecol 2020;223:425.e1–425.e13. https://doi.org/10.1016/j.ajog.2020.02.043

Buddeberg BS, Sharma R, O'Driscoll JM, Kaelin Agten A, Khalil A, Thilaganathan B. Cardiac maladaptation in term pregnancies with preeclampsia. Pregnancy Hypertens 2018;13:198–203. https://doi.org/10.1016/j.preghy.2018.06.015

Simmons LA, Gillin AG, Jeremy RW. Structural and functional changes in left ventricle during normotensive and preeclamptic pregnancy. Am J Physiol Heart Circ Physiol 2002;283:H1627–H1633. https://doi.org/10.1152/ajpheart.00966.2001

Ambrožič J, Lučovnik M, Prokšelj K, Toplišek J, Cvijić M. Dynamic changes in cardiac function before and early postdelivery in women with severe preeclampsia. J Hypertens 2020;38:1367–1374. https://doi.org/10.1097/HJH.0000000000002406

Yu L, Zhou Q, Peng Q, Yang Z. Left ventricular function of patients with pregnancy‐induced hypertension evaluated using velocity vector imaging echocardiography and N‐terminal pro‐brain natriuretic peptide. Echocardiography 2018;35:459–466. https://doi.org/10.1111/echo.13817

Shahul S, Ramadan H, Nizamuddin J, Mueller A, Patel V, Dreixler J, et al. Activin A and late postpartum cardiac dysfunction among women with hypertensive disorders of pregnancy. Hypertension 2018;72:188–193. https://doi.org/10.1161/HYPERTENSIONAHA.118.10888

Buddeberg BS, Sharma R, O'Driscoll JM, Kaelin Agten A, Khalil A, Thilaganathan B. Impact of gestational diabetes mellitus on maternal cardiac adaptation to pregnancy. Ultrasound Obstet Gynecol 2020;56:240–246. https://doi.org/10.1002/uog.21941

Meera SJ, Ando T, Pu D, Manjappa S, Taub CC. Dynamic left ventricular changes in patients with gestational diabetes: A speckle tracking echocardiography study. J Clin Ultrasound 2017;45:20–27. https://doi.org/10.1002/jcu.22399

Aguilera J, Sanchez Sierra A, Abdel Azim S, Georgiopoulos G, Nicolaides KH, Charakida M. Maternal cardiac function in gestational diabetes mellitus at 35‐36 weeks' gestation and 6 months postpartum. Ultrasound Obstet Gynecol 2020;56:247–254. https://doi.org/10.1002/uog.22118

Oliveira AP, Calderon IM, Costa RA, Roscani MG, Magalhaes CG, Borges VT. Assessment of structural cardiac abnormalities and diastolic function in women with gestational diabetes mellitus. Diab Vasc Dis Res 2015;12:175–180. https://doi.org/10.1177/1479164114563302

Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: A systematic review. Diabetes Care 2002;25:1862–1868. https://doi.org/10.2337/diacare.25.10.1862

Li JW, He SY, Liu P, Luo L, Zhao L, Xiao YB. Association of gestational diabetes mellitus (GDM) with subclinical atherosclerosis: A systemic review and meta‐analysis. BMC Cardiovasc Disord 2014;14:132. https://doi.org/10.1186/1471‐2261‐14‐132

Gunderson EP, Chiang V, Pletcher MJ, Jacobs DR, Quesenberry CP, Sidney S, et al. History of gestational diabetes mellitus and future risk of atherosclerosis in mid‐life: The Coronary Artery Risk Development in Young Adults study. J Am Heart Assoc 2014;3:e000490. https://doi.org/10.1161/JAHA.113.000490

Wilson MG, Ellison GM, Cable NT. Basic science behind the cardiovascular benefits of exercise. Heart 2015;101:758–765. https://doi.org/10.1136/heartjnl‐2014‐306596

Richey PA, Brown SP. Pathological versus physiological left ventricular hypertrophy: A review. J Sports Sci 1998;16:129–141. https://doi.org/10.1080/026404198366849

Utomi V, Oxborough D, Whyte GP, Somauroo J, Sharma S, Shave R, et al. Systematic review and meta‐analysis of training mode, imaging modality and body size influences on the morphology and function of the male athlete's heart. Heart 2013;99:1727–1733. https://doi.org/10.1136/heartjnl‐2012‐303465

Weeks KL, McMullen JR. The athlete's heart vs. the failing heart: Can signaling explain the two distinct outcomes? Physiology (Bethesda) 2011;26:97–105. https://doi.org/10.1152/physiol.00043.2010

Kyselovič J, Leddy JJ. Cardiac fibrosis: The beneficial effects of exercise in cardiac fibrosis. Adv Exp Med Biol 2017;999:257–268. https://doi.org/10.1007/978‐981‐10‐4307‐9_14

Maron BJ, Pelliccia A, Spataro A, Granata M. Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. Br Heart J 1993;69:125–128. https://doi.org/10.1136/hrt.69.2.125

Pedlar CR, Brown MG, Shave RE, Otto JM, Drane A, Michaud‐Finch J, et al. Cardiovascular response to prescribed detraining among recreational athletes. J Appl Physiol (1985) 2018;124:813–820. https://doi.org/10.1152/japplphysiol.00911.2017

Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F. Remodeling of left ventricular hypertrophy in elite athletes after long‐term deconditioning. Circulation 2002;105:944–949. https://doi.org/10.1161/hc0802.104534

Luthi P, Zuber M, Ritter M, Oechslin EN, Jenni R, Seifert B, et al. Echocardiographic findings in former professional cyclists after long‐term deconditioning of more than 30 years. Eur J Echocardiogr 2008;9:261–267. https://doi.org/10.1016/j.euje.2007.03.001

Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974;34:29–34. https://doi.org/10.1016/0002‐9149(74)90089‐7

Toedebusch R, Belenchia A, Pulakat L. Diabetic cardiomyopathy: Impact of biological sex on disease development and molecular signatures. Front Physiol 2018;9:453. https://doi.org/10.3389/fphys.2018.00453

Kiencke S, Handschin R, von Dahlen R, Muser J, Brunner‐Larocca HP, Schumann J, et al. Pre‐clinical diabetic cardiomyopathy: Prevalence, screening, and outcome. Eur J Heart Fail 2010;12:951–957. https://doi.org/10.1093/eurjhf/hfq110

Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: A two‐faced disease with restrictive and dilated phenotypes. Eur Heart J 2015;36:1718–1727. https://doi.org/10.1093/eurheartj/ehv134

Battault S, Renguet E, Van Steenbergen A, Horman S, Beauloye C, Bertrand L. Myocardial glucotoxicity: Mechanisms and potential therapeutic targets. Arch Cardiovasc Dis 2020;113:736–748. https://doi.org/10.1016/j.acvd.2020.06.006

Ho KL, Karwi QG, Connolly D, Pherwani S, Ketema EB, Ussher JR, et al. Metabolic, structural and biochemical changes in diabetes and the development of heart failure. Diabetologia 2022;65:411–423. https://doi.org/10.1007/s00125‐021‐05637‐7

van Veldhuisen SL, Gorter TM, van Woerden G, de Boer RA, Rienstra M, Hazebroek EJ, et al. Bariatric surgery and cardiovascular disease: A systematic review and meta‐analysis. Eur Heart J 2022;43:1955–1969. https://doi.org/10.1093/eurheartj/ehac071

Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride JE, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: A population‐based retrospective cohort study. Circulation 2021;143:1468–1480. https://doi.org/10.1161/CIRCULATIONAHA.120.052386

Shah RV, Murthy VL, Abbasi SA, Eng J, Wu C, Ouyang P, et al. Weight loss and progressive left ventricular remodelling: The Multi‐Ethnic Study of Atherosclerosis (MESA). Eur J Prev Cardiol 2015;22:1408–1418. https://doi.org/10.1177/2047487314541731

Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G. Effects of bariatric surgery on cardiac structure and function: A systematic review and meta‐analysis. Am J Hypertens 2014;27:146–156. https://doi.org/10.1093/ajh/hpt215

Sorimachi H, Obokata M, Omote K, Reddy YNV, Takahashi N, Koepp KE, et al. Long‐term changes in cardiac structure and function following bariatric surgery. J Am Coll Cardiol 2022;80:1501–1512. https://doi.org/10.1016/j.jacc.2022.08.738

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2024;26:5–17. https://doi.org/10.1002/ejhf.3024

Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, et al.; SURPASS‐2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503–515. https://doi.org/10.1056/NEJMoa2107519

Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A, et al. The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab 2020;22:2451–2459. https://doi.org/10.1111/dom.14174

Robinson E, Cassidy RS, Tate M, Zhao Y, Lockhart S, Calderwood D, et al. Exendin‐4 protects against post‐myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol 2015;110:20. https://doi.org/10.1007/s00395‐015‐0476‐7

ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS‐CVOT). Identifier: NCT04255433. https://classic.clinicaltrials.gov/ct2/show/NCT04255433 (25 April) 2024.

Takatsu M, Nakashima C, Takahashi K, Murase T, Hattori T, Ito H, et al. Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. Hypertension 2013;62:957–965. https://doi.org/10.1161/HYPERTENSIONAHA.113.02093

Waldman M, Cohen K, Yadin D, Nudelman V, Gorfil D, Laniado‐Schwartzman M, et al. Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ‘SIRT1 and PGC‐1α’. Cardiovasc Diabetol 2018;17:111. https://doi.org/10.1186/s12933‐018‐0754‐4

de Lucia C, Gambino G, Petraglia L, Elia A, Komici K, Femminella GD, et al. Long‐term caloric restriction improves cardiac function, remodeling, adrenergic responsiveness, and sympathetic innervation in a model of postischemic heart failure. Circ Heart Fail 2018;11:e004153. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004153

Koutroumpakis E, Jozwik B, Aguilar D, Taegtmeyer H. Strategies of unloading the failing heart from metabolic stress. Am J Med 2020;133:290–296. https://doi.org/10.1016/j.amjmed.2019.08.035

Fernández‐Solà J. The effects of ethanol on the heart: Alcoholic cardiomyopathy. Nutrients 2020;12:572. https://doi.org/10.3390/nu12020572

Andersson C, Schou M, Gustafsson F, Torp‐Pedersen C. Alcohol intake in patients with cardiomyopathy and heart failure: Consensus and controversy. Circ Heart Fail 2022;15:e009459. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009459

Laonigro I, Correale M, Di Biase M, Altomare E. Alcohol abuse and heart failure. Eur J Heart Fail 2009;11:453–462. https://doi.org/10.1093/eurjhf/hfp037

Rodrigues P, Santos‐Ribeiro S, Teodoro T, Gomes FV, Leal I, Reis JP, et al. Association between alcohol intake and cardiac remodeling. J Am Coll Cardiol 2018;72:1452–1462. https://doi.org/10.1016/j.jacc.2018.07.050

Awtry EH, Philippides GJ. Alcoholic and cocaine‐associated cardiomyopathies. Prog Cardiovasc Dis 2010;52:289–299. https://doi.org/10.1016/j.pcad.2009.11.004

Nicolás JM, Fernández‐Solà J, Estruch R, Paré JC, Sacanella E, Urbano‐Márquez A, et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med 2002;136:192–200. https://doi.org/10.7326/0003‐4819‐136‐3‐200202050‐00007

Guillo P, Mansourati J, Maheu B, Etienne Y, Provost K, Simon O, et al. Long‐term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997;79:1276–1278. https://doi.org/10.1016/s0002‐9149(97)00101‐x

Riehle C, Bauersachs J. Small animal models of heart failure. Cardiovasc Res 2019;115:1838–1849. https://doi.org/10.1093/cvr/cvz161

Conceição G, Heinonen I, Lourenço AP, Duncker DJ, Falcão‐Pires I. Animal models of heart failure with preserved ejection fraction. Neth Heart J 2016;24:275–286. https://doi.org/10.1007/s12471‐016‐0815‐9

Miranda‐Silva D, Gonçalves‐Rodrigues P, Almeida‐Coelho J, Hamdani N, Lima T, Conceição G, et al. Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding‐induced chronic pressure overload. Sci Rep 2019;9:2956. https://doi.org/10.1038/s41598‐019‐39581‐9

Dixon JA, Spinale FG. Large animal models of heart failure: A critical link in the translation of basic science to clinical practice. Circ Heart Fail 2009;2:262–271. https://doi.org/10.1161/CIRCHEARTFAILURE.108.814459

Walther T, Schubert A, Falk V, Binner C, Walther C, Doll N, et al. Left ventricular reverse remodeling after surgical therapy for aortic stenosis: Correlation to renin‐angiotensin system gene expression. Circulation 2002;106:I23–I26. https://doi.org/10.1161/01.cir.0000032919.33237.4d

Spannbauer A, Traxler D, Zlabinger K, Gugerell A, Winkler J, Mester‐Tonczar J, et al. Large animal models of heart failure with reduced ejection fraction (HFrEF). Front Cardiovasc Med 2019;6:117. https://doi.org/10.3389/fcvm.2019.00117

Weinheimer CJ, Kovacs A, Evans S, Matkovich SJ, Barger PM, Mann DL. Load‐dependent changes in left ventricular structure and function in a pathophysiologically relevant murine model of reversible heart failure. Circ Heart Fail 2018;11:e004351. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004351

Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia‐induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709–715. https://doi.org/10.1016/s0735‐1097(96)00592‐x

Mehdizadeh M, Aguilar M, Thorin E, Ferbeyre G, Nattel S. The role of cellular senescence in cardiac disease: Basic biology and clinical relevance. Nat Rev Cardiol 2022;19:250–264. https://doi.org/10.1038/s41569‐021‐00624‐2

Anderson R, Lagnado A, Maggiorani D, Walaszczyk A, Dookun E, Chapman J, et al. Length‐independent telomere damage drives post‐mitotic cardiomyocyte senescence. EMBO J 2019;38:e100492. https://doi.org/10.15252/embj.2018100492

Yáñez‐Bisbe L, Garcia‐Elias A, Tajes M, Almendros I, Rodríguez‐Sinovas A, Inserte J, et al. Aging impairs reverse remodeling and recovery of ventricular function after isoproterenol‐induced cardiomyopathy. Int J Mol Sci 2021;23:174. https://doi.org/10.3390/ijms23010174

Abdellatif M, Trummer‐Herbst V, Heberle AM, Humnig A, Pendl T, Durand S, et al. Fine‐tuning cardiac insulin‐like growth factor 1 receptor signaling to promote health and longevity. Circulation 2022;145:1853–1866. https://doi.org/10.1161/CIRCULATIONAHA.122.059863

Alvandi Z, Bischoff J. Endothelial‐mesenchymal transition in cardiovascular disease. Arterioscler Thromb Vasc Biol 2021;41:2357–2369. https://doi.org/10.1161/ATVBAHA.121.313788

Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, et al. Endothelial to mesenchymal transition in cardiovascular disease: JACC state‐of‐the‐art review. J Am Coll Cardiol 2019;73:190–209. https://doi.org/10.1016/j.jacc.2018.09.089

D'Amario D, Migliaro S, Borovac JA, Restivo A, Vergallo R, Galli M, et al. Microvascular dysfunction in heart failure with preserved ejection fraction. Front Physiol 2019;10:1347. https://doi.org/10.3389/fphys.2019.01347

Liang Y, Ding R, Wang J, Gong X, Yu Z, Pan L, et al. Prediction of response after cardiac resynchronization therapy with machine learning. Int J Cardiol 2021;344:120–126. https://doi.org/10.1016/j.ijcard.2021.09.049

Riolet C, Menet A, Mailliet A, Binda C, Altes A, Appert L, et al. Clinical significance of global wasted work in patients with heart failure receiving cardiac resynchronization therapy. J Am Soc Echocardiogr 2021;34:976–986. https://doi.org/10.1016/j.echo.2021.06.008

Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Subventions

Informations de copyright

Références

Auteurs

Inês Falcão-Pires (I)

Ana Filipa Ferreira (AF)

Fábio Trindade (F)

Luc Bertrand (L)

Michele Ciccarelli (M)

Valeria Visco (V)

Dana Dawson (D)

Nazha Hamdani (N)

Linda W Van Laake (LW)

Frank Lezoualc'h (F)

Wolfgang A Linke (WA)

Ida G Lunde (IG)

Peter P Rainer (PP)

Mahmoud Abdellatif (M)

Jolanda Van der Velden (J)

Nicola Cosentino (N)

Alessia Paldino (A)

Giulio Pompilio (G)

Serena Zacchigna (S)

Stephane Heymans (S)

Thomas Thum (T)

Carlo Gabriele Tocchetti (CG)

Classifications MeSH